Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Disability as an outcome in MS clinical trials.
Cost Analysis of the Use of Glatiramer Acetate Compared to Interferon-Â in Patients with Relapsing-Remitting Multiple Sclerosis and Spasticity in Spain.
Preferential Use of Public TCR during Autoimmune Encephalomyelitis.
MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Pediatric Lyme Neuroborreliosis: Different clinical presentations of the same agent; Single center experience.
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS.
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Advanced MRI and staging of multiple sclerosis lesions.
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
An Electrophoretic Study of the Protein Components in Cerebrospinal Fluid and their Relationship to the Serum Proteins.
Letter to the Editor: Trigeminal neuralgia in patients with multiple sclerosis.
MRI monitoring of spinal cord changes in patients with multiple sclerosis.
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis.
CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity.
Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis.
The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives.
Multiple sclerosis: Real-world long-term benefits of disease-modifying MS therapy.
Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis.
The molecular basis of nutritional intervention in multiple sclerosis: a narrative review.
Multiple sclerosis disease-modifying therapy and pregnancy.
Regional Frontal Perfusion Deficits in Relapsing-Remitting Multiple Sclerosis with Cognitive Decline.
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »